Last reviewed · How we verify
NCT04290572
Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts
Phase 3 trial testing Isotretinoin capsules in Flat Wart in 162 participants. Status unknown.
28 February 2023
Quick facts
| Lead sponsor | Centro Dermatológico Dr. Ladislao de la Pascua |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 162 |
| Start date | 15 March 2020 |
| Primary completion | 28 February 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Isotretinoin capsules — full drug profile →
Conditions studied
- Flat Wart — all drugs for Flat Wart →
Sponsor
Centro Dermatológico Dr. Ladislao de la Pascua
Who can join
Adults 18 to 40, any sex, with Flat Wart. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Randomized clinical trial to compare the efficacy of different doses of oral isotretinoin 10 mg/day, 20 mg/day and 30 mg/day during 12 weeks for the treatment of facial recalcitrant flat warts. The primary endpoint will be the proportion of participants with total remission of facial flat warts at the end of the intervention in the three arms of the clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04290572
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Isotretinoin capsules
Trials testing the same drug.
- NCT06451237 — Acne Remission Maintenance by Weekend Systemic Isotretinoin · Phase 3 · completed
Other recruiting trials for Flat Wart
Currently open trials in the same condition.
- NCT07448844 — Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir · Phase 4 · recruiting
- NCT03977753 — Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatmen · Phase 4 · recruiting
Other Centro Dermatológico Dr. Ladislao de la Pascua trials
Trials by the same sponsor.
- NCT03585179 — Oral and Topical Tranexamic Acid for the Treatment of Melasma · Phase 3 · unknown
- NCT02823236 — Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars · Phase 3 · unknown
- NCT03585140 — Low Glycemic Index and Load Diet for the Treatment of Acne · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04290572 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centro Dermatológico Dr. Ladislao de la Pascua
- Last refreshed: 3 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04290572.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing